National Institute for Health and Care Excellence (2003) Guidance on the Use of Electroconvulsive Therapy (Technology Appraisal Guidance TA59). NICE.
Berrios, GE (1990) Alzheimer's disease: a conceptual history. International Journal of Geriatric Psychiatry, 5: 355–65.
Blandini, F, Cilia R, Cerri S, et al. (2019) Glucocerebrosidase mutations and synucleinopathies: toward a model of precision medicine. Movement Disorders, 34: 9–21.
Blennow, K, Zetterberg, H (2015) The past and the future of Alzheimer's disease CSF biomarkers – a journey toward validated biochemical tests covering the whole spectrum of molecular events. Frontiers in Neuroscience, 9: 345.
Corder, EH, Saunders, AM, Strittmatter, WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261: 921–3.
Courtney, C, Farrell, D, Gray, R, et al. (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 363: 2105–15.
Cubo, E, Shannon, KM, Tracy, D, et al. (2006) Effect of donepezil on motor and cognitive function in Huntington disease. Neurology, 67: 1268–71.
Cummings, J, Lee, G, Ritter, A, et al. (2019) Alzheimer's disease drug development pipeline: 2019. Alzheimer's and Dementia, 5: 272–93.
Debnath, M (2010) Omics Technology. In Molecular Diagnostics: Promises and Possibilities (eds M Debnath M, GB Prasad, PS Bisen): 11–31. Springer.
Erkkinen, MG, Kim, MO, Geschwind, MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology, 10(4): a033118.
Ersek, JL, Black, LJ, Thompson, MA, et al. (2018) Implementing precision medicine programs and clinical trials in the community-based oncology practice: barriers and best practices. American Society of Clinical Oncology Educational Book, 38: 188–96.
Ferrari, R, Manzoni, C, Hardy, J (2019) Genetics and molecular mechanisms of frontotemporal lobar degeneration: an update and future avenues. Neurobiology of Aging, 78: 98–110.
Flaherty, KT, Robert, C, Hersey, P, et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. New England Journal of Medicine, 367: 107–14.
Freudenberg-Hua, Y, Li, W, Davies, P (2018) The role of genetics in advancing precision medicine for Alzheimer's Disease-A narrative review. Frontiers in Medicine, 5: 108.
Goate, A, Chartier-Harlin, MC, Mullan, M, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349: 704–6.
Hampel, H, Vergallo, A, Giorgi, FS, et al. (2018) Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification. Frontiers in Neuroendocrinology, 50: 31–51.
Jordan, VC (2006) Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. British Journal of Pharmacology [Epub ahead of print], Dec 20. Available from: https://doi.org/10.1038/sj.bjp.0706399.
Kaemmerer, WF, Grondin, R (2019) The effects of huntingtin-lowering: what do we know so far? Degenerative Neurological and Neuromuscular Disease, 9: 3–17.
Klunk, WE, Engler, H, Nordberg, A, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Annals of Neurology, 55: 306–19.
Lam, B, Hollingdrake, E, Kennedy, JL, et al. (2009) Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Human Genomics, 4: 91–106.
Lenz, C, Steffen, JA, Engelsberg, A (2013) Molecular testing guidelines for selection of lung cancer patients for ALK tyrosine kinase inhibitors. Journal fur Pharmakologie und Therapie, 22: 45–8.
Matthews, FE, Stephan, BC, Robinson, L, et al. (2016) A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nature Communications, 7: 11398.
McCall, WV, Reboussin, DM, Weiner, RD, et al. (2000) Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy. Archives of General Psychiatry, 57: 438–44.
Mercado, G, Hetz, C (2017) Drug repurposing to target proteostasis and prevent neurodegeneration: accelerating translational efforts. Brain, 140: 1544–7.
Michels, S, Wolf, J (2016) Stratified treatment in lung cancer. Oncology Research and Treatment, 39: 760–6.
Mo, JJ, Li, JY, Yang, Z, et al. (2017) Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis. Annals of Clinical and Translational Neurology, 4: 931–42.
Molinuevo, JL, et al. (2018) Current state of Alzheimer's fluid biomarkers. Acta Neuropathologica, 136: 821–53.
Moraes, F, Góes, A (2016) A decade of human genome project conclusion: scientific diffusion about our genome knowledge. Biochemistry and Molecular Biology Education, 44: 215–23.
Motter, R, Vigo-Pelfrey, C, Kholodenko, D, et al. (1995) Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology, 38: 643–8.
Nikolac Perkovic, M, Pivac, N (2019) Genetic markers of Alzheimer's disease. Advances in Experimental Medicine and Biology, 1192: 27–52.
Quirke, VM (2017) Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. Frontiers in Pharmacology, 8: 620.
Ravikumar, B, Vacher, C, Berger, Z, et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics, 36: 585–95.
Rizzo, G, Arcuti, S, Copetti, M, et al. (2018) Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 89: 358–66.
Sackeim, HA, Decina, P, Kanzler, M, et al. (1987) Effects of electrode placement on the efficacy of titrated, low-dose ECT. American Journal of Psychiatry, 144: 1449–55.
Slamon, DJ, Leyland-Jones, B, Shak, S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344: 783–92.
Sloane, PD, Zimmerman, S, Suchindran, C, et al. (2002) The public health impact of Alzheimer's disease, 2000–2050: potential implication of treatment advances. Annual Review of Public Health, 23: 213–31.
Soverini, S, Abruzzese, E, Bocchia, M, et al. (2019) Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of hematology & oncology, 12: 131.
Stelzmann, RA, Schnitzlein, HN, Murtagh, FR (1995) An English translation of Alzheimer's 1907 paper, “Über eine eigenartige Erkankung der Hirnrinde”. Clinical Anatomy, 8: 429–31.
Strittmatter, WJ, Saunders, AM, Schmechel, D, et al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. PNAS, 90: 1977–81.
Summers, WK, Viesselman, JO, Marsh, GM, et al. (1981) Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biological Psychiatry, 16: 145–53.
Tabrizi, SJ, Leavitt, BR, Landwehrmeyer, GB, et al. (2019) Targeting huntingtin expression in patients with Huntington's disease. New England Journal of Medicine, 380: 2307–16.
Trusheim, MR, Burgess, B, Hu, SX, et al. (2011) Quantifying factors for the success of stratified medicine. Nature Reviews Drug Discovery, 10: 817–33.
Venter, JC, Adams, MD, Myers, EW, et al. (2001) The sequence of the human genome. Science, 291: 1304–51.
Yu, H, Burton, B, Huang, CJ, et al. (2012) Ivacaftor potentiation of multiple CFTR channels with gating mutations. Journal of Cystic Fibrosis, 11(3): 237–45.